Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer by Nong Y, Qin H, Wei L, Wei X, Lv J, Huang X, Wu B

Subjects: Get full text

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer by Vesna Ćeriman Krstić, Dragana Jovanović, Natalija Samardžić, Milija Gajić, Jelena Kotur Stevuljević, Aleksandra Klisic, Ivan Soldatović, Damir Radončić, Marina Roksandić Milenković, Biljana Šeha, Nikola Čolić, Katarina Lukić, Milan Savić

Subjects: Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Subjects: Get full text

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer by Shun Lu, Jian Fang, Ziping Wang, Yun Fan, Yunpeng Liu, Jianxing He, Jianying Zhou, Jie Hu, Jinjing Xia, Wenxin Liu, Jane Shi, Jing Yi, Lejie Cao

Subjects: Get full text

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed... by Alvin H.K. Cheung, MBBS, PhD, Zeta Mui, MPhil, Walter W. Yeung, PhD, Chit Chow, PhD, Mandy F. Yu, BSc, Olivia H. Chen, MD, PhD, Kit-Yee Wong, MPhil, Fuda Xie, MPhil, Yat Ming Lau, MBBS, Alfred S-L. Cheng, PhD, Wei Kang, PhD, Ka-Fai To, MBChB, Tony S. Mok, MD, Molly S.C. Li, MBBS

Subjects: Get full text

A phase 2 study of frontline pembrolizumab in follicular lymphoma by Carrie Ho, Songli Zhu, Ted Gooley, Taranjit S. Gujral, Ryan C. Lynch, Christina Poh, Mazyar Shadman, Stephen D. Smith, Yolanda Tseng, Ajay K. Gopal

Subjects: Get full text

Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes by Medine Dicleli, Ayşe Nur Keleş, Ulaş Alabalik

Subjects: Get full text

Hubungan Ekspresi PD-L1 dengan Derajat Diferensiasi dan Staging Karsinoma Sel Skuamosa Paru di RSUP Dr.M.Djamil Padang by iftahillah - iftahillah, aswiyanti - asri, yenita - yenita, Henny - Mulyani, Afriani - Afriani, sondang - nora, Husna - Yetti

Subjects: “…pd-l1…”
Get full text

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis by Hongbin Lu, Lulu Luo, Jie Mi, Min Sun, Huaping Wang, Zheng Wang, Wenwen Ding

Subjects: “…PD-L1…”
Get full text

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles by Paola A. Castagnino, Derick A. Haas, Luca Musante, Nathalia A. Tancler, Bach V. Tran, Rhonda Kean, Alexandra R. Steck, Luis A. Martinez, Elahe A. Mostaghel, D. Craig Hooper, Felix J. Kim

Subjects: Get full text

Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy by Yu Z, Zhou Z, Zhao Y

Subjects: “…pd-l1…”
Get full text

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: “…Anti-PD-1/PD-L1…”
Get full text

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment by Yifu Shu, Jing Li

Subjects: Get full text

Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma by Li-Jun Wei, Zi-Yun Wu, Li-Yan Wu, Ying-Wen Wu, Hao-Yu Liang, Rong-Zhen Luo, Li-Li Liu

Subjects: “…PD-L1…”
Get full text

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC by Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S. Schaefer

Subjects: Get full text

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab by Jaejun Lee, Jaejun Lee, Jae-Sung Yoo, Ji Hoon Kim, Ji Hoon Kim, Dong Yeup Lee, Keungmo Yang, Keungmo Yang, Bohyun Kim, Joon-Il Choi, Jeong Won Jang, Jeong Won Jang, Jong Young Choi, Jong Young Choi, Seung Kew Yoon, Seung Kew Yoon, Ji Won Han, Ji Won Han, Pil Soo Sung, Pil Soo Sung

Subjects: “…PD-L1…”
Get full text

Enhancing cancer care with improved checkpoint inhibitors by Vickram A S, Saghya Infant Shofia, A. Saravaran, Vidhya Lakshmi Sivakumar, Packiyam Thamarai, Manikandan Sivasubramanian, Shivani Chopra, Hitesh Chopra

Subjects: Get full text

ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Recept... by Chiba N, Menju T, Shimazu Y, Toyazaki T, Sumitomo R, Miyamoto H, Tamari S, Nishikawa S, Date H

Subjects: Get full text

Prevalence of HPV in anal cancer: exploring the role of infection and inflammation by Fatemeh Ebrahimi, Reyhaneh Rasizadeh, Sajjad Jafari, Hossein Bannazadeh Baghi

Subjects: Get full text

A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China by Hongmei Li, Yuliang Yuan, Qianjie Xu, Guangzhong Liang, Zuhai Hu, Xiaosheng Li, Wei Zhang, Haike Lei

Subjects: Get full text